A carregar...
Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Nearly 70% of breast cancer (BC) is hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and endocrine therapy is the mainstay of treatment for this subtype. However, intrinsic or acquired endocrine resistance can occur during the endocrine treatment. Based on in...
Na minha lista:
| Publicado no: | Chin Med J (Engl) |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wolters Kluwer Health
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7213629/ https://ncbi.nlm.nih.gov/pubmed/32265426 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CM9.0000000000000745 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|